Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial

Benzer Materyaller

• Osimertinib in first line setting: preventive or delayed T790M occurrence?
  Yazar:: Sun, Hao, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Primary resistance to osimertinib despite acquired T790M
  Yazar:: Chang, Ling‐Kai, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
  Yazar:: Akamatsu, Hiroaki, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI
  Yazar:: Okuma, Yusuke, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status
  Yazar:: Nishii, Yoichi, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)